ADHD: Evaluation of Current and Emerging Therapies (Wave 2)

Our Markets

Our Services

Specialties:

ADHD: Evaluation of Current and Emerging Therapies (Wave 2)

A Survey of 25 Psychiatrists, 24 Pediatricians, and 25 Pediatric Psychiatrists

January 2008

Deliverable: Survey with key findings.

Study Description:

Topic	ADHD
Respondent Type	Physicians
Specialties Covered	Psychiatry & Pediatrics
Region	United States Only
Methodology	Online survey, self-administered via a Panel Intelligence website Duration: 15 minutes Size: 60 respondents Fielding Dates: December 18^th, 2007 to January 7^th, 2008

Objectives:

To understand the use of ADHD medications (specifically Vyvnase and generic Adderall)

· Quantify current treatment practices in child, adolescent, and patient populations

· Understand the future use of Vyvnase and generic Adderall under different co-payment scenarios

· Identify the perceived clinical differences between Vyvnase and other drugs

Companies and Products Mentioned in This Report:

Company	Ticker Symbol	Product(s)
Shire	SHPGY	Adderall XR (amphetamine mixed salts), Daytrana (methylphenidate transdermal system), Vyvnase
Alza (a division of J & J)	JNJ	Concerta (methylphenidate hydrochloride)
Novartis	NVS	Focalin XR (dexmethylphenidate hydrochloride), Ritalin LA & SR (methylphenidate)
Lilly	LLY	Strattera (atomoxetine)

Inclusion Criteria and Respondent Demographics:

Inclusion Criteria

§ 25 Psychiatrists, 24 pediatricians, and 25 pediatric psychiatrists

§ Board-certified or board-eligible in given specialty

§ At least 15 ADHD patients currently treated

§ Currently prescribes medications for ADHD

§ 2 to 30 years of practice experience

§ Spend at least 40% of professional time in clinical practice

Reports become free one year after the publication date.

about us